Longevity medicine faces a major challenge in translating promising research into safe, practical protocols for everyday use, risking safety and credibility.

Addressing this issue requires better translational frameworks, including clear protocols, educational resources, and higher standards for vendors to ensure transparency and scientific accuracy.

Longevity enthusiast Michael Martin shares his personal experience with methylene blue dosing, illustrating the confusion caused by conflicting information from various sources.

This dosing gap undermines clinical adoption, investor confidence, and the credibility of the field, especially when vendors provide inadequate guidance.

Converting research dosages into practical instructions involves complex steps prone to errors, leading many to rely on guesswork or abandon promising interventions.

Michael Martin has developed Protocol Buddy, a platform designed to help users with dosing calculations and safety considerations, exemplifying technological solutions to this challenge.

Establishing standards for translational medicine in longevity could influence other emerging medical fields, promoting responsible growth and innovation.

The future success of longevity medicine depends on collaboration among researchers, clinicians, vendors, and users to build trust, safety, and infrastructure for sustainable progress.